Intellia Therapeutics, Inc. Tech Stack

Intellia Therapeutics, Inc. uses 8 technology products and services including cdnjs, SurveyMonkey, AngularJS, and more. Explore Intellia Therapeutics, Inc.'s tech stack below.

  • cdnjs
    Content Delivery Network
  • SurveyMonkey
    Customer Feedback Management
  • AngularJS
    Javascript Frameworks
  • Revslider
    Miscellaneous
  • Cisco Meraki
    Network Hardware
  • Java
    Programming Languages
  • Smartsheet
    Project Management
  • Adobe Creative Suite
    Visualisation Software

Media & News

Intellia Therapeutics, Inc.'s Email Address Formats

Intellia Therapeutics, Inc. uses at least 4 format(s):
Intellia Therapeutics, Inc. Email FormatsExamplePercentage
firstlast@intelliatx.comJohnDoe@intelliatx.com
54%
last@intelliatx.comDoe@intelliatx.com
17%
first.l@intelliatx.comJohn.D@intelliatx.com
17%
firlast@intelliatx.comJohDoe@intelliatx.com
12%

Frequently Asked Questions

Where is Intellia Therapeutics, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc.'s main headquarters is located at 40 Erie Street Cambridge, Massachusetts 02139 US. The company has employees across 5 continents, including North AmericaEuropeAsia.

What is Intellia Therapeutics, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Intellia Therapeutics, Inc.'s main corporate office by phone at +1-617-909-7579. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Intellia Therapeutics, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc. is a publicly traded company; the company's stock symbol is NTLA.

What is Intellia Therapeutics, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc.'s official website is intelliatx.com and has social profiles on LinkedIn.

How much revenue does Intellia Therapeutics, Inc. generate?

Minus sign iconPlus sign icon
As of March 2024, Intellia Therapeutics, Inc.'s annual revenue reached $750M.

What is Intellia Therapeutics, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Intellia Therapeutics, Inc. have currently?

Minus sign iconPlus sign icon
As of March 2024, Intellia Therapeutics, Inc. has approximately 614 employees across 5 continents, including North AmericaEuropeAsia. Key team members include CEO: N. B.Chief Scientific Officer: L. S.Chief Medical Officer: D. L.. Explore Intellia Therapeutics, Inc.'s employee directory with LeadIQ.

What industry does Intellia Therapeutics, Inc. belong to?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc. operates in the Biotechnology Research industry.

What technology does Intellia Therapeutics, Inc. use?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc.'s tech stack includes cdnjsSurveyMonkeyAngularJSRevsliderCisco MerakiJavaSmartsheetAdobe Creative Suite.

What is Intellia Therapeutics, Inc.'s email format?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc.'s email format typically follows the pattern of firstlast@intelliatx.com. Find more Intellia Therapeutics, Inc. email formats with LeadIQ.

How much funding has Intellia Therapeutics, Inc. raised to date?

Minus sign iconPlus sign icon
As of March 2024, Intellia Therapeutics, Inc. has raised $790M in funding. The last funding round occurred on Jan 01, 2016 for $100M.

When was Intellia Therapeutics, Inc. founded?

Minus sign iconPlus sign icon
Intellia Therapeutics, Inc. was founded in 2014.
Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

Biotechnology ResearchMassachusetts, United States501-1000 Employees

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help.

Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology’s attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.

View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .

Section iconCompany Overview

Headquarters
40 Erie Street Cambridge, Massachusetts 02139 US
Phone number
+1-617-909-7579
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
NTLA
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2014
Employees
501-1000

Section iconFunding & Financials

  • $790M

    Intellia Therapeutics, Inc. has raised a total of $790M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2016 in the amount of $100Mas a public offering.

  • $100M$1B

    Intellia Therapeutics, Inc.'s revenue is in the range of $100M$1B

Section iconFunding & Financials

  • $790M

    Intellia Therapeutics, Inc. has raised a total of $790M of funding over 2 rounds. Their latest funding round was raised on Jan 01, 2016 in the amount of $100Mas a public offering.

  • $100M$1B

    Intellia Therapeutics, Inc.'s revenue is in the range of $100M$1B

© LeadIQ, Inc. All rights reserved.